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Background: Plasma-derived C1 inhibitor (C1-INH) concentrate is a treatment option for 
acute hereditary angioedema (HAE) attacks and is considered the standard-of-care in many 
countries, although it is not yet available in the United States. Studies are still being conducted 
to establish its safety and efﬁ  cacy as required by the FDA.
Objective: To review the medical literature to determine if C1-INH concentrate is a safe and 
effective treatment for acute HAE attacks.
Methods: The following keywords were searched in PubMed and OVID: C1 esterase inhibitor, 
C1-inhibitor, C1 inhibitor, and hereditary angioedema treatment. English-language articles 
were searched from 1966 to the present to look for studies demonstrating the efﬁ  cacy and the 
safety of C1-INH concentrate.
Results: The English-language literature search revealed several studies showing signiﬁ  cantly 
improved relief of HAE symptoms with the administration of C1-INH concentrate – many studies 
demonstrated some improvement of symptoms within 30 minutes. Side effects have been similar 
to placebo, and no proven cases of viral transmission have occurred in over 20 years.
Conclusion: C1-INH concentrate appears to be a very safe and effective treatment option 
for HAE.
Keywords: hereditary angioedema, c1 inhibitor, c1 esterase inhibitor, hereditary angioedema 
treatment
Introduction
Hereditary angioedema (HAE) is an autosomal dominant inherited condition caused 
by a quantitative or qualitative deﬁ  ciency of C1-esterase inhibitor (C1-INH). C1-INH 
is the main regulator of the early steps of the classic complement pathway. Without 
C1-INH, uncontrolled activation of the classic pathway of the complement system can 
occur, along with the activation of other inﬂ  ammatory mediators. In addition to the 
suppressive effect on the complement pathway, C1-INH also inhibits the kallikrein-
kinin system, bradykinin activation, lectin pathway, plasmin, and factors 11a and 12a 
of the coagulation pathway. Presently, the unregulated activation of bradykinin is 
thought to cause the changes we call angioedema (Schneider et al 2007). Angioedema 
can either occur spontaneously or after a traumatic or stressful event, which leads to 
edema formation. The condition is characterized by acute attacks of sudden edema 
formation in the skin or in the walls of the upper respiratory tract or gastrointestinal 
tract. Cases of laryngeal edema can rapidly become life threatening. Cases of gastroin-
testinal attacks have been misdiagnosed and have lead to unnecessary surgeries (Ohela 
et al 1973). The clinical course, triggers, and frequency of attacks can be difﬁ  cult to 
predict. The approach to treatment has two main goals: one is to prevent acute attacks 
of hereditary angioedema from developing, and the other is to rapidly terminate acute 
angioedema attacks if they do occur.Therapeutics and Clinical Risk Management 2008:4(5) 976
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The prevention of HAE attacks should begin with practical 
measures, which include avoidance of trauma and other 
interventions. Some medications can predispose an HAE 
patient to increased episodes of angioedema – these include 
estrogens and ACE inhibitors, which both should be avoided 
in patients with HAE. Patients are also likely to do better if 
conditions like gastritis and Helicobacter pylori infections are 
treated (Rais et al 1999; Visy et al 2007). Long-term prophy-
laxis for patients with HAE has been achieved in some cases 
with antiﬁ  brinolytics, C1-INH and attenuated androgens.
Epsilon-aminocaproic acid (EACA) is an antiﬁ  brinolytic 
agent used to treat HAE, and doses of 8–10 g per day have 
been shown to reduce frequency and severity of HAE attacks. 
Side effects of this medication include muscle discomfort, 
postural hypotension, sedative properties, and menstrual 
discomfort that is caused by the clotting of menstrual blood. 
In addition to these side effects is the theoretical risk of 
thrombophilia (Frank et al 1976). A contraindication to the 
use of EACA is a history of thrombosis and epilepsy. In 
countries outside the US, tranexamic acid has also been used 
as prophylaxis, but is not approved for use in the US.
Attenuated androgens have also been used as prophylaxis 
for acute attacks of HAE. Danazol is the attenuated androgen 
most often prescribed to treat HAE, and is used in adults at 
doses of 50–200 mg 1 to 3 times daily and in some cases 
every other day therapy is effective. Once it has been initi-
ated, its dose can often be titrated down slowly as tolerated in 
order to minimize its side effects. Some of these side effects 
include masculinization, acne, voice deepening, hirsutism, 
weight gain, and anxiety. This medication can also affect the 
liver, so liver function tests must be monitored. Additionally, 
danazol can slow growth in children and is contraindicated 
during pregnancy due to the possibility of masculinization of 
a female fetus. While attenuated androgens have been shown 
to be an effective agent, they do have signiﬁ  cant dose-related 
side effects that can limit their use (Hosea et al 1980).
In many countries C1-INH is used for the treatment of 
acute HAE attacks; however, C1-INH is not yet approved 
in some countries, including the US. Thus, there are limited 
treatment options for acute HAE attacks in these areas, but 
several other products are being studied in clinical trials 
that may soon be available (Table 1). One such product 
is a recombinant human C1-INH (rhC1-INH) (Rhucin®; 
Pharming, Leiden, The Netherlands). This product is made 
by the introduction of a human C1-INH gene into rabbits. 
Speciﬁ  cally, the C1-inhibitor gene construct is under the 
milk-speciﬁ  c casein promoter for expression in rabbit milk. 
This recombinant C1-INH is then secreted into rabbit milk 
and is puriﬁ  ed. Initial studies show that infusion of 100 units 
per kg body weight (U/kg) of this product is effective in ter-
minating acute attacks of HAE with initiation of improvement 
recorded at a median time of 0.5 hours after infusion. How-
ever, the half-life of this product is 3 hours, which is shorter 
than the reported half-life of C1-INH concentrate, which is 
36–48 hours. The shorter half-life of recombinant C1-INH is 
due to differences in glycosylation of this product. The pos-
sible beneﬁ  ts of recombinant C1-INH include its theoretical 
reduced risk of viral transmission and that its production is 
not dependent on plasma donations. One drawback includes 
the potential for allergic reactions to rabbit proteins. Also, 
the short half-life raises concern for relapses of acute HAE 
attacks, although no relapses were reported in recent studies 
(van Doorn et al 2005; Choi et al 2007).
Ecallantide® (Dyax Corp., Cambridge, MA, USA) is 
another product currently being studied for the treatment of 
acute HAE attacks. Decreased levels of C1-INH are believed 
to allow increased activation of the kallikrein cascade leading 
to an increase in bradykinin as a mechanism of angioedema. 
Ecallantide is a recombinant protein produced by the Pichia 
pastoris strain of yeast. It acts as a direct kallikrein inhibitor, 
blocking its action and preventing the downstream forma-
tion of bradykinin. It can be administered intravenously or 
subcutaneously. A recent randomized, double-blind, placebo-
controlled clinical trial was conducted which demonstrated 
that the median time from infusion to the beginning of effect 
was 30.5 minutes. Patients in the study received a dose ranging 
Table 1 A comparison of developing treatments for acute hereditary angioedema attacks in the US
Method of production Mechanism of action Half-life Infusion method FDA status
Berinert P® Plasma concentrate C1-inhibitor 36–48 h iv Pending FDA approval
Cinryze® Plasma concentrate C1-inhibitor 20–92 h iv Pending FDA approval
Rhucin® Recombinant protein C1-inhibitor 3 h iv Was not FDA approved
Ecallantide® Recombinant protein Kallikrein inhibitor 1–4 h Subcutaneous Pending resubmission to the FDA
Icatibant® Synthetic peptide Bradykinin-2 receptor antagonist 1–4 h Subcutaneous Was not approved by the FDA
Abbreviation: h, hours; iv, intravenous.Therapeutics and Clinical Risk Management 2008:4(5) 977
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from 5 to 40 mg/m2 intravenously, and 29 of 40 (72.5%) 
patients reported signiﬁ  cant improvement within 4 hours, 
which was statistically signiﬁ  cant compared with 2 of 8 (25%) 
in placebo. This is a promising study which demonstrates that 
Ecallantide® may be another potent therapy for acute HAE 
attacks in the near future (Schneider et al 2007).
Icatibant (Jerini, Berlin, Germany) is yet another product 
being studied for the treatment of acute HAE attacks. Icatibant 
is a synthetic agent that can be administered intravenously 
or subcutaneously. It is similar in structure to bradykinin 
and acts as a selective bradykinin-2 receptor antagonist. 
One uncontrolled study examined Icatibant at 3 different 
intravenous doses and 2 different subcutaneous doses (Bork 
et al 2007). The median time to onset of symptom relief was 
reduced from the historical data of 42 hours without treat-
ment to 1.16 hours with Icatibant. While this study was not 
a controlled trial, it demonstrated good evidence of potential 
beneﬁ  ts of this therapy.
Where C1-INH concentrate is unavailable, fresh frozen 
plasma (FFP) has also been used with success to treat acute 
attacks of angioedema (Pickering et al 1969). However, 
because FFP also contains other substrates, including 
kininogens, there is a potential to worsen some acute attacks 
of HAE (Rosen and Austen 1969). Despite this potential risk, 
several groups still treat acute attacks of HAE with FFP when 
C1-INH concentrate is unavailable (Prematta et al 2007) with 
the knowledge that the beneﬁ  t and adverse effect proﬁ  le of 
C1-INH is superior to that of FFP.
As mentioned above, C1-INH concentrate has been 
available for greater than 20 years in parts of Europe for 
the treatment of acute HAE attacks, and it is currently 
considered the standard of care in many countries (Gompels 
et al 2005). However, C1-INH concentrate is unavailable in 
many countries including the US. Currently, two different 
companies are involved in clinical trials to introduce 
C1-INH to the US. CSL Behring (Marburg, Germany) is 
investigating Berinert P®, while Lev Pharmaceuticals (New 
York, NY, USA) is investigating Cinryze® for approval in 
the US. The purpose of this paper is to review the current 
literature on C1-INH concentrate and evaluate its safety and 
efﬁ  cacy in the treatment of HAE.
Methods
The literature was searched to review the data demonstrating 
the efﬁ  cacy and safety of C1-INH for the treatment of acute 
HAE attacks. The following search terms were used in 
PubMed and OVID: C1 esterase inhibitor, C1-inhibitor, C1 
inhibitor, and hereditary angioedema treatment. English-
language articles were searched from 1966 to the present to 
look for studies demonstrating the efﬁ  cacy and the safety of 
C1-INH concentrate.
Results
In 1980, Gadek et al (1980) published a manuscript on the 
treatment of HAE with C1-INH protein that was removed 
from pooled plasma via chromatography. They referred to 
1 unit (U) of C1-INH as being the amount of C1-INH found 
in 1 mL of plasma, which is still the terminology used. 
The group demonstrated the effect of puriﬁ  ed C1-INH in 
vivo in patients with HAE when given between 410 and 
1000 U of C1 inhibitor to 8 patients with HAE. 3 patients 
were given the product during asymptomatic periods and 5 
patients were given the inhibitor during acute HAE attacks. 
All of the symptomatic patients experienced improvement 
of symptoms with C1-INH infusion. Their symptoms began 
to improve within 30 minutes and were completely resolved 
within 5–7 hours. C1-INH and C4 levels were measured after 
plasma infusion. Gadek et al demonstrated that C1-INH lev-
els peaked rapidly and dropped quickly; however, C4 levels 
peaked approximately 6 hours after the C1-INH levels, and 
the C4 levels remained elevated for a much longer period of 
time. None of the patients demonstrated any adverse reactions 
related to C1-INH concentrate treatment.
Waytes et al (1996) published the first randomized, 
double-blind, placebo-controlled trial on C1-INH concentrate. 
This product was puriﬁ  ed from plasma and vapor-heated to 
inactivate viruses. The group tested C1-INH concentrate used 
as both a prophylactic agent and as an agent to treat acute 
attacks of HAE. The infusion dose of C1-INH was 25 U/kg 
body weight in both groups. The prophylactic group was 
investigated as a cross-over study in which 6 patients were 
Table 2 Suggested follow-up of patients treated with plasma-
derived C1 inhibitor (C1-INH)
Baseline assessment 
prior to starting C1-INH
Test Frequency
LFTs Baseline
HIV serology Baseline
HepB-surface ag Baseline
HCV-Ab Baseline
Give hepatitis 
B vaccine
Baseline (series 
of 3 injections)
Twelve-month intervals LFTs Every 12 months
Note: Presently no guidelines exist for serial assessment of patients on C1-INH in 
the US and the table includes information that is expected to be included in future 
guidelines.
Abbreviation: LFTs, liver function tests.Therapeutics and Clinical Risk Management 2008:4(5) 978
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randomly assigned to receive C1-INH or placebo infusion 
every 3 days in two different 17-day treatment periods to 
evaluate for a difference in the frequency of acute attacks. 
Disease activity was reduced 60% during the C1-INH 
treatment period compared with the placebo treatment period. 
Also from that publication was a study on acute HAE attacks 
in which patients were randomly assigned to receive C1-INH 
concentrate versus placebo for acute treatment. Patients 
treated with C1-INH showed a signiﬁ  cantly shorter mean 
time from infusion to the initial signs of improvement of 
symptoms (55 minutes versus 563 minutes). Moreover, 38 of 
55 attacks (69%) treated with C1-INH concentrate had some 
improvement within 30 minutes of infusion compared with 
1 of 49 (2%) attacks in the placebo group. Patients had no 
serious short-term side effects from receiving C1-INH and 
were monitored for up to 4 years without anyone developing 
HIV, hepatitis B, or hepatitis C.
Another randomized, double-blind, placebo-controlled 
trial was conducted by Kunschak et al (1998). They compared 
11 patients treated for acute HAE attacks with 25 U/kg body 
weight of C1 INH (60 total treatments) with 11 patients 
treated with placebo for acute HAE attacks (57 total treat-
ments). The mean time from infusion to the earliest sign of 
symptom relief was signiﬁ  cantly shorter in patients given 
C1-INH concentrate compared with placebo. The mean time 
from infusion to complete resolution of symptoms was also 
signiﬁ  cantly shorter in the treatment group: 23.98 hours in the 
treatment group compared with 34.98 hours in the placebo 
group. However, because the placebo data included 49 of 
the 57 treatments that required open-label C1-INH as rescue 
therapy, the difference between these two groups is probably 
underestimated. Kunschak et al also studied the half-life 
of C1-INH by investigating both functional and antigenic 
C1-INH levels. They found that the mean functional C1-INH 
half-life was 38.87 ± 19.75 hours, and the mean antigenetic 
C1-INH half-life was 24.01 ± 9.70 hours. They also noted 
that serum C4 concentrations remained elevated much longer 
than C1-INH levels – staying at peak levels at least 24 hours 
post C1-INH infusion. They also reviewed the viral safety 
of C1-INH concentrate and found that of the 22 patients 
receiving a total of 157 C1-INH concentrate infusions, there 
was no evidence of viral infections. Only minor adverse reac-
tions related to C1-INH were reported and included 1 patient 
with nausea and bad aftertaste, 1 patient with shortness of 
breath, and 1 patient with dizziness and headache.
As stated previously, C1-INH concentrate has been 
available for HAE treatment for many years in parts of Europe 
and several groups have published their personal results for 
the treatment of acute HAE attacks with C1-INH. Bork and 
Barnstedt (2001) compiled data from HAE patients in Germany 
who received C1-INH concentrate for laryngeal edema and 
compared the length of attacks with patients who had laryngeal 
edema in the past, but did not receive C1-INH concentrate. 
The study was not double-blinded or placebo-controlled as 
everyone was treated with C1-INH concentrate when it was 
available. The group treated 18 patients for a total of 193 epi-
sodes of laryngeal edema with 500–1000 U of C1-INH. Most 
of the patients treated with C1-INH had some improvement of 
symptoms within 1 hour with a mean time of 42.2 minutes. The 
group found that the patients treated with C1-INH concentrate 
for symptoms of laryngeal edema had an average duration of 
symptoms of 15.3 ± 9.3 hours which was signiﬁ  cantly shorter 
than patients who did not receive C1-INH concentrate and had 
a mean duration of symptoms of 100.8 ± 26.2 hours.
Bork et al (2005) retrospectively examined acute 
abdominal attacks of HAE and compared 75 patients with 
17,444 untreated acute abdominal attacks to 4,834 acute 
abdominal attacks treated with C1-INH concentrate (Bork 
et al 2005). The usual dose of C1-INH concentrate was 500 U; 
however, higher doses were given if a clinical response was 
not achieved, or if the patient’s weight was over 80 kg, then 
they were treated with 1000 U of C1-INH concentrate. The 
mean duration of an acute abdominal attack was signiﬁ  cantly 
shorter at 30.3 ± 23.2 hours when treated with C1-INH con-
centrate compared with 93.8 ± 42.7 hours when patients were 
not treated for their attacks. However, the group also noted that 
C1-INH concentrate seemed to have a more dramatic effect 
on an acute attack if given early in the course of the attack. 
Patients often needed a larger amount of C1-INH if they were 
treated later for their acute attack. Bork et al noted that the 
mean time from injection to initial improvement of symptoms 
varied depending on the timing of infusion; 53.5 minutes if 
C1-INH concentrate was given within 2 hours of the onset of 
an attack compared with 114 minutes if C1-INH was given 
greater than 2 hours after the onset of symptoms. This group 
also examined the safety of C1-INH concentrate in these 
patients. They reported no HIV, hepatitis B, or hepatitis 
C transmission after C1-INH concentrate administration. 
The only adverse effects were faintness, vertigo, headaches, 
reddened face, feeling of warmth or coldness, paresthesias, 
coldness, fevers, and chills in a small group of patients. All of 
the patients who had some side effects were reportedly able 
to receive subsequent infusions and had fewer side effects 
with additional treatments.
Farkas et al (2007) reviewed a group of patients treated 
for HAE with C1-INH from 1996 to 2006. The patients, Therapeutics and Clinical Risk Management 2008:4(5) 979
Plasma-derived C1 inhibitor for hereditary angioedema
22 children and 39 adults, were treated for a total of 468 
acute attacks, which included 230 abdominal attacks and 
133 cases of laryngeal edema. C1-INH successfully treated 
the symptoms in all of the patients; for most, 500 U were 
required; however, 9 patients required an additional 500 U 
to achieve symptom control. Eight of these 9 were due to 
laryngeal edema triggered by an airway infection. The group 
also examined a subset of the patients to determine average 
time between receiving C1-INH and the ﬁ  rst signs of clini-
cal improvement. On average, laryngeal edema symptoms 
started to improve within 15 minutes of receiving C1-INH, 
while abdominal symptoms started to improve within 30 
minutes. The improvement in subcutaneous edema usually 
took longer than 30 minutes. Patients were also followed for 
adverse reactions or hepatitis B, hepatitis C, or HIV trans-
mission, and none of the 61 patients had any severe adverse 
effects or viral transmission after C1-INH therapy.
A poster presentation from the 2007 ACAAI meeting 
presented a randomized, double-blind, placebo-controlled 
trial with 68 subjects receiving nanoﬁ  ltered C1-INH versus 
placebo for the treatment of acute HAE attacks involving the 
abdomen, face, or genitourinary area. They demonstrated 
signiﬁ  cantly shorter time from treatment infusion to “begin-
ning of unequivocal relief” in the C1-INH treatment group 
(n = 35; median time = 2 hours) versus placebo group (n = 33; 
median time 4 hours) (Zuraw et al 2007).
At the 2008 AAAAI Meeting, 3 abstract presentations 
reported some of the most recent trials with C1-INH concen-
trate. The IMPACT 1 (International Multicenter Prospective 
Angioedema C1-INH Trials) involved 125 HAE patients 
randomly assigned to receive 1 of 3 different treatments for 
acute HAE attacks (Bernstein et al 2008): placebo; 10 U/kg 
of C1-INH; 20 U/kg of C1-INH. The time from the treatment 
infusion to the beginning of improvement was signiﬁ  cantly 
shorter in the group treated with 20 U/kg of C1-INH (median 
time 30 minutes) versus placebo (median time 90 minutes). 
However, the group treated with the 10 U/kg C1-INH infu-
sion was not signiﬁ  cantly shorter (median time 70 minutes). 
There was no reported viral seroconversion after C1-INH 
administration. Only minor side effects were reported which 
were actually more common in the placebo group.
The IMPACT 2 is an open-label North American study 
in which 39 subjects were treated for 355 episodes of 
HAE acute attacks with 20 U/kg of C1-INH (Craig et al 
2008). Median time to the beginning of symptom relief 
after administration of the C1-INH was 30 minutes – the 
same as that in the IMPACT 1 Trial. The time from infu-
sion to the beginning of relief of symptoms was similar 
in all types of HAE attacks: for laryngeal attacks median 
time was 25 minutes; for abdominal attacks the median 
time was 26 minutes; for both peripheral and facial attacks 
median time was 32 minutes. There were no conﬁ  rmed viral 
seroconversions during this study.
Another poster presentation, from the 2008 AAAAI 
meeting, demonstrated the use of C1-INH as a prophylactic 
treatment. Twenty-two patients were involved in a 24-week 
cross-over study receiving C1-INH 1000 U twice weekly 
for 12 weeks and placebo (normal saline) treatment for 
12 weeks. The subjects had fewer attacks during the C1-INH 
treatment period than the placebo period (mean 6.1 versus 
12.7, p  0.0001) (Zuraw et al 2008).
Because some patients with HAE are subject to frequent 
attacks, several groups have examined C1-INH concentrate 
infusions at home so patients do not have to obtain urgent 
care each time they have an attack (Levi et al 2006; Longhurst 
et al 2007). This includes Levi et al who assessed the option 
of self-administration of C1-inhibitor concentrate in patients 
with HAE as well as patients with acquired angioedema. In 
their study, patients were taught to establish intravenous 
access and infuse C1-INH at home. They enrolled only 
patients with frequent attacks for two different studies: 
one group of 12 patients received C1-INH regularly to pre-
vent acute attacks, and the other group of 31 patients had 
C1-INH available at home “on demand” for the treatment 
of acute attacks. In the “on demand” group, when the patient 
administered the C1-INH at home, the time from symptom 
onset to treatment was reduced compared with those who 
had to travel to a hospital (1.4 ± 1.0 hours compared to 
3.4 ± 2.1 hours). More importantly, the time to complete 
resolution of symptoms was even more reduced (5.9 ± 2.2 
hours versus 13.8 ± 2.9 hours), which is a reﬂ  ection that 
earlier treatment may be more effective and lead to a more 
rapid resolution, as seen in other studies (Bork et al 2005). 
The second study group received C1-INH as a prophylactic 
treatment at home. At the time of enrollment, patients had 
exacerbations at least once every 10 days and an average of 
4 attacks per month. These patients were then treated with 
a prophylactic dose of 1000 U of C1-INH approximately 
every 5–7 days (mean 6.8 days). The patients had a sig-
niﬁ  cant reduction in the number of attacks – 7 of 12 had 
no angioedema attacks after prophylaxis, 3 of 12 had fewer 
than 1 attack every 6 months, and 2 of 12 had fewer than 
1 attack in 3 months. The overall angioedema attack rate 
decreased from a mean of 4 attacks per month to 0.3 attacks 
per month. Patients had no serious reactions. These studies 
demonstrated that home administration of C1-INH has the Therapeutics and Clinical Risk Management 2008:4(5) 980
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potential to be quite beneﬁ  cial. Patients receive treatment 
much earlier than they otherwise might, which reduces the 
duration of symptoms. In addition, the prophylactic portion 
demonstrated that weekly to biweekly injections could reduce 
and at times eliminate attacks.
Discussion
C1-INH concentrate has been available in parts of Europe 
for over 20 years with many studies showing strong evidence 
that it signiﬁ  cantly shortens an acute HAE attack. However, 
many of the studies are based on retrospective data because 
until recently, only a limited number of randomized, placebo-
controlled, double-blind clinical trials to establish its efﬁ  cacy 
were available. Ethically, it is difﬁ  cult to withhold C1-INH 
concentrate to a patient with an acute attack because some 
attacks can be very serious or fatal; therefore, most studies 
have used open-label C1-INH concentrate for urgent condi-
tions in patients receiving the placebo. Multiple groups have 
presented their data for C1-INH concentrate with apparent 
success, but given the fact that an acute attack can have an 
unpredictable course with sudden worsening or improvement, 
it is difﬁ  cult to prove efﬁ  cacy without assessing varied doses 
in a placebo-controlled and double-blinded clinical trial.
Several recent articles have demonstrated the efﬁ  cacy 
of C1-INH concentrate for the treatment of acute HAE 
attacks. The doses given in these studies have ranged from 
400 to 1000 U and in other studies have ranged from 10 to 
25 U/kg body weight. The most recent studies used 20 U/kg 
body weight as the dose for treatment. Several groups have 
demonstrated that the time from infusion to the beginning 
of relief of symptoms is faster than 1 hour and some have 
shown that the time to ﬁ  rst symptom improvement is within 
30 minutes. One study even showed that 95% of patients have 
some response within 60 minutes of receiving C1-INH (Craig 
et al 2008). Laryngeal edema attacks seem to respond most 
rapidly to treatment followed by abdominal, then facial and 
peripheral attacks. Shorter times from the onset of symptoms 
to the infusion of C1-INH (especially within 2 hours) seem 
to be associated with faster and more effective improvement 
of symptoms.
One of the drawbacks of comparing these studies is that 
the criteria to determine which types of attacks to treat were 
not consistent from study to study. It seems reasonable to 
treat any attack causing a patient distress. Since HAE is a 
complex disease, predicting when a patient’s symptoms may 
become worse can be very difﬁ  cult.
Several groups also demonstrated that C1-INH concen-
trate infusions given regularly can prevent acute attacks. 
The intervals at which C1-INH concentrate is given for 
prophylaxis can vary considerably, with one study dem-
onstrating a reduction in acute attacks with infusion every 
3 days (Waytes et al 1996), and another study demonstrating 
a reduction in attacks with infusions every 5–7 days (Levi 
et al 2006). It is interesting that the half-life of C1-INH has 
been reported to be from 36 to 48 hours (Bernstein 2008), so 
one might think that infusions given every 5–7 days would 
not be adequate. However, the study by Levi et al (2006) 
does indeed demonstrate improvement in symptoms with 
this interval, suggesting that even increasing C1-INH levels 
slightly can result in signiﬁ  cant reduction of HAE attacks. 
This is consistent with the observations that C4 levels peak 
several hours after C1-INH levels and remain elevated for 
a longer period of time, demonstrating a biochemical effect 
that exceeds the serum half-life of C1-INH levels. However, 
the actual frequency of C1-INH infusions should probably be 
tailored on an individual basis, attempting to eliminate acute 
attacks with the lowest necessary frequency of C1-INH treat-
ment. The data from these studies support the use of C1-INH 
concentrate for long-term prophylaxis for either patients 
that continue to have attacks despite prophylactic therapy 
with agents like attenuated androgens, or for patients with 
unwanted side effects related to androgen treatment.
Several authors have demonstrated home therapy as a 
potential option for patients with HAE. Levi et al (2006), 
as mentioned previously, demonstrated a signiﬁ  cant reduc-
tion in attack frequency in patients with scheduled C1-INH 
concentrate self-infusions at home. They also demonstrated 
faster treatment and improvement of acute attacks when 
patients were able to treat themselves at home. Patients in 
their study were successful in self-administering an intrave-
nous catheter and infusion at home in 98% of cases. Initiating 
home therapy would require a signiﬁ  cant amount of patient 
education on safely administering infusions. Patients should 
also be educated on symptoms that would require immediate 
medical attention. Certainly, in a case of laryngeal edema, 
a patient should ﬁ  rst call their emergency number before 
attempting a home infusion. In cases of abdominal attacks, 
patients should call their physician or report to the hospital 
if their symptoms are at all different from typical attacks or 
if they are not resolving with therapy. Patients with HAE 
can certainly develop other abdominal conditions that may 
present similarly. These studies demonstrate that if done in 
the appropriate environment with adequate education and 
patient understanding, home C1-INH concentrate infusion 
for prophylaxis or acute treatment is a promising therapy 
leading to signiﬁ  cant improvement of quality of life, faster Therapeutics and Clinical Risk Management 2008:4(5) 981
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and more effective treatment of attacks, reduced frequency 
of acute HAE attacks, and fewer hospitalizations.
While C1-INH concentrate appears very effective 
from clinical trials, its safety is also very important. Since 
C1-INH concentrate is puriﬁ  ed from human plasma, there is 
a theoretical risk of transmission of infectious agents such as 
hepatitis B, hepatitis C, HIV, and other viruses. The safety 
of C1-INH concentrate is ensured through multiple steps. 
The initial step is plasma donor selection. Individual donors 
are screened for risk factors for viral diseases along with 
elevated ALT. In 1986, the donor screening for HIV began 
and was added to hepatitis B serology screening. Serologic 
testing for hepatitis C began in 1993, and has since advanced 
to include screening for other viruses. In 1985, the safety of 
C1-INH concentrate improved after the introduction of a step 
in which the concentrate was heated for 10 hours at 60 °C to 
inactivate viruses (Cicardi et al 1995). Also, one company 
now uses a nanoﬁ  ltration step in which a 15 nm ﬁ  lter is used 
to remove viruses and even prions (Terpstra et al 2007). 
None of the studies using either Lev’s or CSL Behring’s 
products have found any evidence of viral seroconversion 
with C1-INH concentrate infusions; however, earlier stud-
ies before viral inactivation procedures demonstrated HCV 
transmission secondary to C1-INH from Immuno produced 
C1-INH (Cicardi et al 1995). One of the main C1-INH prod-
ucts is Berinert P®, and the company that produces it claims 
that over 100 million units of Berinert P® have been admin-
istered with no proven cases of viral transmission (Juers and 
Groner 2004). Thus, it appears to be a very safe treatment 
with few reported side effects compared with placebo and 
no proven viral infections in association with infusion since 
the introduction of the heat step. Similarly, Cinryze® has 
been used in Europe both in trials and clinical use and has 
no evidence of viral transmission (Lev, pers comm).
Based on over 20 years of data, including recently 
completed double-blind, placebo-controlled trials, C1-INH 
concentrate appears to be very effective in the treatment 
of acute HAE attacks. The only other currently available 
treatment for acute attacks is FFP, which is a controversial 
treatment. C1-INH concentrate does not have the other sub-
strates that FFP carries that give FFP the theoretical risk of 
worsening an attack. C1-INH also has the added beneﬁ  t of 
increased viral safety compared with FFP due to the puriﬁ  -
cation and pasteurization steps performed. No studies have 
compared C1-INH concentrate with any of the new emerging 
therapies. These alternative therapies may prove to be as 
effective for acute attacks, but will unlikely be utilized for 
prophylaxis secondary to their short half-lives.
Conclusion
C1-INH concentrate is considered standard of care in many 
countries for the treatment of HAE, and will likely soon 
be available in the US. Studies have shown it to be a very 
effective treatment with improvement of symptoms within 
30 minutes to one hour. It appears very safe with no proven 
viral transmission since the introduction of the heat step. 
The side effect proﬁ  le in a recent study was very similar to 
placebo. In addition to treating acute HAE attacks, it may 
also be beneﬁ  cial as a chronic prophylactic agent, and may 
one day be approved for home infusion in properly selected 
patients with appropriate training. The present data on 
C1-INH concentrate appear very promising, and the avail-
ability of C1-INH concentrate in more countries will improve 
quality of life and productivity, as well as reduce anxiety and 
disability for patients with HAE.
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